Emerging roles of PDGF-D in EMT progression during tumorigenesis

Cancer Treatment Reviews

Volumn 39, Issue 6, 2013, Pages 640-646

  Wu, Qiong ^a   Hou, Xin ^a   Xia, Jun ^a   Qian, Xiujuan ^a   Miele, Lucio ^b   Sarkar, Fazlul H ^c   Wang, Zhiwei ^a,d  

^a BENGBU MEDICAL COLLEGE   (China)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

EMT; Invasion; Migration; MiRNA; Natural compounds; PDGF D; Stem cells

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; FLAVONE; ILORASERTIB; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; PLATELET DERIVED GROWTH FACTOR D; PROTEIN BCL 2; SUNITINIB; TRICIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; KIDNEY CANCER; LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LYMPHOKINES; PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84878905949     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.11.006     Document Type: Review

References (111)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62:220-241.
3. Gatenby R.A., Gillies R.J., Brown J.S. Evolutionary dynamics of cancer prevention. Nat Rev Cancer 2010, 10:526-527.
4. Luch A. Nature and nurture - lessons from chemical carcinogenesis. Nat Rev Cancer 2005, 5:113-125.
5. Bertrand F.E., Angus C.W., Partis W.J., Sigounas G. Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle 2012, 11.
6. Piazzi G., Bazzoli F., Ricciardiello L. Epigenetic silencing of Notch signaling in gastrointestinal cancers. Cell Cycle 2012, 11.
7. Wang Z., Li Y., Ahmad A., Azmi A.S., Banerjee S., Kong D., et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 2010, 1806:258-267.
8. Gonzalez E., McGraw T.E. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 2009, 8:2502-2508.
9. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562.
10. Ng J.M., Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer 2011, 11:493-501.
11. Jagani Z., Dorsch M., Warmuth M. Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle 2010, 9:3449-3456.
12. Klaus A., Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008, 8:387-398.
13. Perkins N.D. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 2012, 12:121-132.
14. Nogueira L., Ruiz-Ontanon P., Vazquez-Barquero A., Moris F., Fernandez-Luna J.L. The NFkappaB pathway: a therapeutic target in glioblastoma. Oncotarget 2011, 2:646-653.
15. Demchenko Y.N., Kuehl W.M. A critical role for the NFkB pathway in multiple myeloma. Oncotarget 2010, 1:59-68.
16. Huang W., Fridman Y., Bonfil R.D., Ustach C.V., Conley-Lacomb M.K., Wiesner C., et al. A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth. Oncogene 2012, 31:4527-4535.
17. Lokker N.A., Sullivan C.M., Hollenbach S.J., Israel M.A., Giese N.A. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002, 62:3729-3735.
18. Ustach C.V., Huang W., Conley-LaComb M.K., Lin C.Y., Che M., Abrams J., et al. A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res 2010, 70:9631-9640.
19. Ustach C.V., Kim H.R. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 2005, 25:6279-6288.
20. Xu L., Tong R., Cochran D.M., Jain R.K. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 2005, 65:5711-5719.
21. Zhao L., Zhang C., Liao G., Long J. RNAi-mediated inhibition of PDGF-D leads to decreased cell growth, invasion and angiogenesis in the SGC-7901 gastric cancer xenograft model. Cancer Biol Ther 2010, 9:42-48.
22. Kong D., Banerjee S., Ahmad A., Li Y., Wang Z., Sethi S., et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010, 5:e12445.
23. Kong D., Li Y., Wang Z., Banerjee S., Ahmad A., Kim H.R., et al. MiR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009, 27:1712-1721.
24. Kong D., Wang Z., Sarkar S.H., Li Y., Banerjee S., Saliganan A., et al. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008, 26:1425-1435.
25. Devarajan E., Song Y.H., Krishnappa S., Alt E. Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells. Int J Cancer 2012, 131:1023-1031.
26. Sethi S., Sarkar F.H., Ahmed Q., Bandyopadhyay S., Nahleh Z.A., Semaan A., et al. Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol 2011, 4:222-226.
27. Wang Z., Ali S., Banerjee S., Bao B., Li Y., Azmi A.S., et al. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. J Cell Physiol 2012.
28. Reigstad L.J., Varhaug J.E., Lillehaug J.R. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J 2005, 272:5723-5741.
29. Li X., Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev 2003, 14:91-98.
30. Conley-LaComb M.K., Huang W., Wang S., Shi D., Jung Y.S., Najy A., et al. PTEN regulates PDGF ligand switch for beta-PDGFR signaling in prostate cancer. Am J Pathol 2012, 180:1017-1027.
31. Ustach C.V., Taube M.E., Hurst N.J., Bhagat S., Bonfil R.D., Cher M.L., et al. A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res 2004, 64:1722-1729.
32. Liu M.Y., Eyries M., Zhang C., Santiago F.S., Khachigian L.M. Inducible platelet-derived growth factor D-chain expression by angiotensin II and hydrogen peroxide involves transcriptional regulation by Ets-1 and Sp1. Blood 2006, 107:2322-2329.
33. Najy A.J., Won J.J., Movilla L.S., Kim H.R. Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer. Mol Cancer Res 2012, 10:1087-1097.
34. Ahmad A., Wang Z., Kong D., Ali R., Ali S., Banerjee S., et al. Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways. Breast Cancer Res Treat 2011, 126:15-25.
35. Kong D., Banerjee S., Huang W., Li Y., Wang Z., Kim H.R., et al. Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res 2008, 68:1927-1934.
36. Wang Z., Kong D., Banerjee S., Li Y., Adsay N.V., Abbruzzese J., et al. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res 2007, 67:11377-11385.
37. Okada A., Yaguchi T., Kanno T., Gotoh A., Nakano T., Nishizaki T. PDGF-D/PDGF-betabeta receptor-regulated chemotaxis of malignant mesothelioma cells. Cell Physiol Biochem 2012, 29:241-250.
38. Wang Z., Ahmad A., Li Y., Kong D., Azmi A.S., Banerjee S., et al. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta 2010, 1806:122-130.
39. Wang Z., Kong D., Li Y., Sarkar F.H. PDGF-D signaling: a novel target in cancer therapy. Curr Drug Targets 2009, 10:38-41.
40. Yang S., Shin J., Park K.H., Jeung H.C., Rha S.Y., Noh S.H., et al. Molecular basis of the differences between normal and tumor tissues of gastric cancer. Biochim Biophys Acta 2007, 1772:1033-1040.
41. LaRochelle W.J., Jeffers M., Corvalan J.R., Jia X.C., Feng X., Vanegas S., et al. Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer. Cancer Res 2002, 62:2468-2473.
42. Floege J., Eitner F., Van Roeyen C., Ostendorf T. PDGF-D and renal disease: yet another one of those growth factors?. J Am Soc Nephrol 2003, 14:2690-2691.
43. Fredriksson L., Li H., Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004, 15:197-204.
44. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
45. Zlobec I., Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010, 1:651-661.
46. Wang Z., Li Y., Ahmad A., Azmi A.S., Kong D., Banerjee S., et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 2010, 13:109-118.
47. Kang Y., Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004, 118:277-279.
48. Fuxe J., Vincent T., Garcia de Herreros A. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 2010, 9:2363-2374.
49. Grego-Bessa J., Diez J., Timmerman L., de la Pompa J.L. Notch and epithelial-mesenchyme transition in development and tumor progression: another turn of the screw. Cell Cycle 2004, 3:718-721.
50. Bao B., Wang Z., Ali S., Kong D., Banerjee S., Ahmad A., et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem 2011, 112:2296-2306.
51. Maitah M.Y., Ali S., Ahmad A., Gadgeel S., Sarkar F.H. Up-regulation of sonic hedgehog contributes to TGF-beta1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One 2011, 6:e16068.
52. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-348.
53. Sabatini D.M. MTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006, 6:729-734.
54. Oh W.J., Jacinto E. MTOR complex 2 signaling and functions. Cell Cycle 2011, 10:2305-2316.
55. Shor B., Gibbons J.J., Abraham R.T., Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009, 8:3831-3837.
56. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011, 12:21-35.
57. Foster D.A., Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle 2009, 8:1026-1029.
58. Gulhati P., Bowen K.A., Liu J., Stevens P.D., Rychahou P.G., Chen M., et al. MTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 2011, 71:3246-3256.
59. Lamouille S., Connolly E., Smyth J.W., Akhurst R.J., Derynck R. TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci 2012, 125:1259-1273.
60. Radtke F., Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor?. Nat Rev Cancer 2003, 3:756-767.
61. Wang Z., Li Y., Sarkar F.H. Notch signaling proteins: legitimate targets for cancer therapy. Curr Protein Pept Sci 2010, 11:398-408.
62. Ranganathan P., Weaver K.L., Capobianco A.J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011, 11:338-351.
63. Efstratiadis A., Szabolcs M., Klinakis A. Notch, Myc and breast cancer. Cell Cycle 2007, 6:418-429.
64. Chen X., Stoeck A., Lee S.J., Shih IeM., Wang M.M., Wang T.L. Jagged1 expression regulated by Notch3 and Wnt/beta-catenin signaling pathways in ovarian cancer. Oncotarget 2010, 1:210-218.
65. Piazzi G., Fini L., Selgrad M., Garcia M., Daoud Y., Wex T., et al. Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget 2011, 2:1291-1301.
66. Wang Z., Li Y., Kong D., Sarkar F.H. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets 2010, 11:745-751.
67. Bao B., Wang Z., Ali S., Kong D., Li Y., Ahmad A., et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011, 307:26-36.
68. Lu T., Stark G.R. Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle 2004, 3:1114-1117.
69. Fraser C.C. Exploring the positive and negative consequences of NF-kappaB inhibition for the treatment of human disease. Cell Cycle 2006, 5:1160-1163.
70. Min C., Eddy S.F., Sherr D.H., Sonenshein G.E. NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem 2008, 104:733-744.
71. Osipo C., Golde T.E., Osborne B.A., Miele L.A. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest 2008, 88:11-17.
72. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002, 2:647-656.
73. Quinn L.M., Richardson H. Bcl-2 in cell cycle regulation. Cell Cycle 2004, 3:7-9.
74. Shroff E.H., Snyder C., Chandel N.S. Role of Bcl-2 family members in anoxia induced cell death. Cell Cycle 2007, 6:807-809.
75. Choi J., Choi K., Benveniste E.N., Rho S.B., Hong Y.S., Lee J.H., et al. Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2. Cancer Res 2005, 65:5554-5560.
76. Trisciuoglio D., Desideri M., Ciuffreda L., Mottolese M., Ribatti D., Vacca A., et al. Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol 2005, 205:414-421.
77. Trisciuoglio D., Gabellini C., Desideri M., Ragazzoni Y., De Luca T., Ziparo E., et al. Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. Cell Death Differ 2011, 18:1024-1035.
78. Trisciuoglio D., Gabellini C., Desideri M., Ziparo E., Zupi G., Del Bufalo D. Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PLoS One 2010, 5:e11772.
79. Wang X., Belguise K., Kersual N., Kirsch K.H., Mineva N.D., Galtier F., et al. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 2007, 9:470-478.
80. Sun T., Sun B.C., Zhao X.L., Zhao N., Dong X.Y., Che N., et al. Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology 2011, 54:1690-1706.
81. Epstein R.J. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 2004, 4:901-909.
82. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
83. Domanska U.M., Kruizinga R.C., Nagengast W.B., Timmer-Bosscha H., Huls G., de Vries E.G., et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2012.
84. Li X., Ma Q., Xu Q., Liu H., Lei J., Duan W., et al. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett 2012, 322:169-176.
85. Liu J., Liao S., Huang Y., Samuel R., Shi T., Naxerova K., et al. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res 2011, 17:3638-3648.
86. van Kouwenhove M., Kedde M., Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 2011, 11:644-656.
87. Medina P.P., Slack F.J. microRNAs and cancer: an overview. Cell Cycle 2008, 7:2485-2492.
88. Deng S., Calin G.A., Croce C.M., Coukos G., Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008, 7:2643-2646.
89. Kasinski A.L., Slack F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011, 11:849-864.
90. Yokobori T., Suzuki S., Tanaka N., Inose T., Sohda M., Sano A., et al. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducers ZEB1. Cancer Sci 2012.
91. Han M., Wang Y., Liu M., Bi X., Bao J., Zeng N., et al. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1alpha expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci 2012, 103:1058-1064.
92. Han M., Liu M., Wang Y., Chen X., Xu J., Sun Y., et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 2012, 7:e39520.
93. Cao M., Seike M., Soeno C., Mizutani H., Kitamura K., Minegishi Y., et al. MiR-23a regulates TGF-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol 2012, 41:869-875.
94. Scheel C., Weinberg R.A. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012, 22:396-403.
95. Kong D., Li Y., Wang Z., Sarkar F.H. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins?. Cancers (Basel) 2011, 3:716-729.
96. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
97. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012, 12:133-143.
98. Scheel C., Weinberg R.A. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells?. Int J Cancer 2011, 129:2310-2314.
99. Brabletz T. To differentiate or not - routes towards metastasis. Nat Rev Cancer 2012, 12:425-436.
100. Morel A.P., Lievre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3:e2888.
101. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007, 14:3629-3637.
102. Brooks C., Sheu T., Bridges K., Mason K., Kuban D., Mathew P., et al. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat Oncol 2012, 7:154.
103. Glaser K.B., Li J., Marcotte P.A., Magoc T.J., Guo J., Reuter D.R., et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families. J Pharmacol Exp Ther 2012.
104. Taeger J., Moser C., Hellerbrand C., Mycielska M.E., Glockzin G., Schlitt H.J., et al. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 2011, 10:2157-2167.
105. Zhou Y., Chen Y., Tong L., Xie H., Wen W., Zhang J., et al. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. J Cell Mol Med 2012, 16:2321-2330.
106. Sanford M., Scott L.J. Imatinib: as adjuvant therapy for gastrointestinal stromal tumour. Drugs 2010, 70:1963-1972.
107. Andrae N., Kirches E., Hartig R., Haase D., Keilhoff G., Kalinski T., et al. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Eur J Cancer 2012, 48:1831-1841.
108. Najy A.J., Jung Y.S., Won J.J., Conley-LaComb M.K., Saliganan A., Kim C.J., et al. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Prostate 2012, 72:1328-1338.
109. Seki N., Toh U., Kawaguchi K., Ninomiya M., Koketsu M., Watanabe K., et al. Tricin inhibits proliferation of human hepatic stellate cells in vitro by blocking tyrosine phosphorylation of PDGF receptor and its signaling pathways. J Cell Biochem 2012, 113:2346-2355.
110. Hawthorne T., Giot L., Blake L., Kuang B., Gerwien R., Smithson G., et al. A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther 2008, 46:236-244.
111. Li Y., VandenBoom T.G., Kong D., Wang Z., Ali S., Philip P.A., et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009, 69:6704-6712.